ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effectiveness of Simethicone In Improving Visibility During Colonoscopy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00615303
Recruitment Status : Completed
First Posted : February 14, 2008
Last Update Posted : February 22, 2013
Sponsor:
Information provided by (Responsible Party):
Abhasnee Sobhonslidsuk, Ramathibodi Hospital

Brief Summary:
Sodium phosphate is one of the bowel preparation regimens for colonoscopy. However, intraluminal gas can impair visibility during the examination. Simethicone is medication that works by reducing the surface tension of air bubbles. We aimed to evaluate the effect of simethicone in enhancing visibility and efficacy during colonoscopy.

Condition or disease Intervention/treatment Phase
Colonoscopy Drug: Simethicone Drug: Placebo Phase 4

Detailed Description:
A prospective, randomized, double-blinded, placebo-controlled study was conducted. One hundred and twenty-four patients were allocated to receive 2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day. The colonoscopic examination was recorded. Visibility was blindly assessed for the amount of air bubbles and the degree of haziness by a single investigator. Five areas of the colon were graded for the amount of air bubbles, from 0 to 3; grade 0 and 1 were defined as the diminishing of air bubbles. The haziness was graded into 5 levels from excellent to unacceptable. Excellent, good and adequate were defined as the diminishing of haziness. The total duration of colonoscopy, the side effect of medication and the endoscopist and patient satisfaction were compared between 2 groups. Endoscopist satisfaction was evaluated by questionnaires. Visual analog scale (0-10) was used for rating patient satisfaction and the side effect of medication.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 194 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effectiveness of Simethicone In Improving Visibility During Colonoscopy: A Randomized, Placebo-controlled Study
Study Start Date : December 2006
Actual Primary Completion Date : December 2007
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Colonoscopy
U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: 2 Drug: Placebo
2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day
Other Name: Sodium phosphate
Active Comparator: 1 Drug: Simethicone
2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day. The colonoscopic examination was recorded
Other Name: sodium phosphate



Primary Outcome Measures :
  1. Visibility: air bubble and haziness [ Time Frame: During colonoscopy ]

Secondary Outcome Measures :
  1. Total colonoscopic time, patient and doctor satisfaction and side effects [ Time Frame: During colonscopy ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- Patients with age 18-70 yrs old who undergo colonoscopy at the endoscopic unit of the hospital

Exclusion Criteria:

  • Renal insufficiency (Cr >2.3 mg/dl)
  • Congestive heart failure
  • Massive ascites
  • Acute myocardial infarction within 6 months
  • Coagulopathy
  • Previous colonic surgery
  • Suspected of colonic obstruction Pregnancy Refuse to give inform consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00615303


Locations
Thailand
Ramathibodi hospital
Bangkok, Thailand, 10400
Sponsors and Collaborators
Ramathibodi Hospital
Investigators
Study Director: Abhasnee Sobhonslidsuk, M.D. Ramathibodi Hospital

Responsible Party: Abhasnee Sobhonslidsuk, Associate professor, Ramathibodi Hospital
ClinicalTrials.gov Identifier: NCT00615303     History of Changes
Other Study ID Numbers: ID12-49-23
ID12-49-23 ( Other Grant/Funding Number: Gastroenterological Association of Thailand )
First Posted: February 14, 2008    Key Record Dates
Last Update Posted: February 22, 2013
Last Verified: February 2013

Keywords provided by Abhasnee Sobhonslidsuk, Ramathibodi Hospital:
Bowel preparation, colonoscopy, simethicone, air bubble

Additional relevant MeSH terms:
Simethicone
Antifoaming Agents
Molecular Mechanisms of Pharmacological Action
Emollients
Dermatologic Agents